

Current best practice for disease activity assessment in IBD

Alissa J. Walsh^{1*}, Robert V. Bryant^{2,3*} and Simon P. L. Travis¹

¹Translational Gastroenterology Unit, Experimental Medicine Division, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, United Kingdom

². Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia

³School of Medicine, University of Adelaide, Adelaide, South Australia, 5005, Australia.

**These authors are joint first authors.*

Correspondence to A.J.W

alissa.walsh@linacre.ox.ac.uk

Key points:

- Objective assessment of disease activity assessment in IBD is important for guiding subsequent therapy as a part of a 'treat to target' strategy
- Multiple domains of disease activity assessment exist in IBD (symptoms, endoscopy, histology, radiology, biomarkers and quality of life), and targets should be recognized as goals for therapy within each domain
- Confusing terminology and the use of composite indices (combining symptom assessment with objective measurements of quality of life or inflammation) confound the formal evaluation of disease activity
- Biomarkers are useful adjuncts to monitor disease activity in both ulcerative colitis and Crohn's disease
- Assessment of quality of life is an important aspect of medical decision-making, as improving quality of life is a major goal of therapy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Abstract

Therapeutic advances in the management of IBD have led to a paradigm shift in the assessment of IBD disease activity. Beyond clinical remission, objective assessment of inflammation is now critical to guiding subsequent therapy as part of a ‘treat to target’ strategy. Multiple domains of disease activity assessment in IBD exist, each of which has its merits, although none are perfect. The aim of this Review is to comprehensively evaluate measures of disease activity in both ulcerative colitis and Crohn’s disease, including clinical, endoscopic, histological and radiological assessment tools, as well as the use of biomarkers and quality of life (QOL) evaluation. A subjective appraisal of the best indices for use in clinical practice is provided, based on index validation, responsiveness and experience in clinical trials, international specialist opinion, and practicality and suitability for use in clinical practice. The aim of this Review is to enable the reader to gain confidence in IBD disease activity assessment and to give ready access to the necessary tools.

1 Management of IBD is guided by the anatomical distribution of disease, symptom
2 severity, response to medical therapy and the ability of the patient to accept and
3 tolerate treatment.^{1,2} Disease severity indices help to guide clinical decisions and are
4 particularly helpful for patients who fail to show adequate response to therapy as
5 they clearly show (in a quantitative manner) that they have not met the desired
6 target. (Table 1, 2). Advances such as increased availability and use of biologic
7 agents for the treatment of IBD have led to a paradigm shift in the assessment of
8 disease activity as we are now better able to achieve remission targets. Beyond
9 clinical remission, ongoing treatment strategies require guidance from objective
10 assessment of disease activity. IBD disease activity comprises multiple domains that
11 can be assessed; each of these domains has its merits, although none are perfect
12 (FIG 1.).

13
14 The aim of this Review is to evaluate measures of disease activity assessment in
15 both ulcerative colitis and Crohn's disease. Formal evaluation of disease activity in
16 IBD is associated with many challenges, including confusing terminology, different
17 names or abbreviations for the same index, and the tendency to use composite
18 indices that combine symptom assessment with objective measures of inflammation
19 or quality of life (QOL).

20
21 To make this summary clinically useful, we have divided the paper into sections on
22 ulcerative colitis and Crohn's disease; in each we will discuss clinical, endoscopic,
23 histological and radiological assessment, as well as biomarkers and QOL. A
24 subjective evaluation of the best disease activity indices for use in clinical practice is
25 provided. Remission thresholds for disease activity indices are also provided when

possible. The indices were selected after several considerations: extent of validation; responsiveness and experience in clinical trials; international expert opinion; ³ active comparison between all indices in clinical practice; ⁴ and ease of use in clinical practice. Although to some extent the choice of indices was that of the authors, the selection is informed by our extensive involvement in index development, evaluation, formal guideline development, clinical trials and clinical practice. ³⁻⁹ This Review aims to give the reader ready access to appropriate assessment tools, and enable the reader to gain confidence in IBD disease activity assessment. A comprehensive list of relevant disease activity indices is provided as a supplementary table for both ulcerative colitis and Crohn's disease (see [Supplementary information S1 \(tables 1 and 2, respectively\) online](#)).

A good case can be made (and one that we advocate) for separating the components of disease activity assessment, using distinct and independently validated clinical, endoscopic, histological and QOL indices. We recognize that this might as yet represent a minority view, but we believe it will gain ground, particularly as QOL becomes an important outcome measure for care.

[H1] Ulcerative colitis

[H3] Clinical assessment of disease activity.

There are 17 ulcerative colitis indices that evaluate symptoms, eight of which do so independently of endoscopic scoring or biochemical markers (see [Supplementary information S1 \(table 1\) online](#)). For assessment of mild to moderate ulcerative colitis we recommend the Simple Colitis Clinical Activity index (SCCAI),¹⁰ Partial Mayo Clinic Index^{11,12} and the Pediatric Ulcerative Colitis Activity Index (PUCAI).¹³ For severe disease, we recommend Truelove and Witts' criteria.¹⁴

The SCCAI (see [Supplementary information S2 \(table 1\) online](#)) is one of the eight indices that excludes endoscopic assessment and biochemical markers. Importantly, it includes nocturnal bowel movements and urgency of defecation.¹⁰ These symptoms are of vital importance to patients due to their effect on QOL, but are neglected by other indices. Scores in this index range from 0 to 19 points. The SCCAI has been compared prospectively with the multiple other ulcerative colitis indices and, along with the PUCAI, performed best of all noninvasive indices for validity, reliability, responsiveness (ability to measure the change in disease activity) and feasibility. This index was sufficiently able to discriminate remission from active disease.¹⁵ As the SCCAI does not include a Physician's Global Assessment or biochemical markers, it can readily be completed by patients. The remission target is a SCCAI total score of <1.³

The Partial Mayo Clinic Index (see [Supplementary information S2 \(table 2\) online](#)) is currently the most widely used index in trial design.^{11,12} The full Mayo Clinic Index

(Partial Mayo Clinic Index plus endoscopic subscore) has become the standard for assessing disease activity in adult clinical trials in which endoscopic assessment is mandated by the FDA.¹⁶ Rectal bleeding and frequency of bowel motions are the only two symptoms assessed. Although readily criticized because it is an unvalidated derivation of an unvalidated index, when the Partial Mayo Index was compared with other noninvasive indices, this index performed well for discriminating remission from active disease, showed responsiveness and good construct validity. Insufficient test–retest validity were shown.¹⁵ A Global Physician assessment is necessary for the Partial Mayo Index and therefore makes it less feasible for clinical use [Au:OK?] .

The remission target is a Partial Mayo total score of ≤ 1 .³

The PUCAI (see [Supplementary information S2 \(table 3\) online](#)) was devised by paediatric gastroenterologists as a noninvasive instrument to assess disease activity in children; repeated endoscopy in this setting is less tolerable to both patients and parents.¹³ This index comprises six descriptors, each with different levels, creating a total score ranging from 0 to 85: abdominal pain, degree of rectal bleeding, average stool consistency, number of stools in 24 h, presence of nocturnal stools and patient activity level are assessed. The PUCAI was rigorously developed and validated in children,¹³ and has also been shown to be valid, reliable and responsive in adults.¹⁵ This index permits less frequent endoscopic assessment for all patients with ulcerative colitis, both in clinical practice and clinical trials.¹⁵ The remission target is a PUCAI total score of <10 .³

For severe disease assessment and management we encourage the use of the Truelove and Witts' criteria (see [Supplementary information S2 \(table 4\) online](#)).¹⁴

This index provides objective criteria to identify acute severe colitis, and has been widely used to define the need for hospital admission and intravenous steroids.¹⁷ The criteria for acute severe colitis are ≥ 6 stools per day, with frequent blood in the stool, with at least one of the following features: body temperature $>37.8^{\circ}\text{C}$; heart rate >90 bpm, haemoglobin levels <10.5 g/dL [Au:OK?] and erythrocyte sedimentation rate >30 mm/h. Patients with more of these criteria present at admission have a greater chance of needing a colectomy on that admission.¹⁸

[H3]Endoscopic assessment of disease activity.

Mucosal healing is the remission target when assessing IBD disease activity endoscopically. . Simply stated, mucosal healing should imply the absence of ulceration and erosions. Nevertheless, there is currently no validated definition of mucosal healing in IBD.^{16,19,20}

Mucosal healing should be recognized as the ultimate therapeutic goal for ulcerative colitis, as the disease is limited to the mucosa.¹⁹ Thus, endoscopic assessment of patients with ulcerative colitis is increasingly used in clinical practice to guide treatment decision-making. Mucosal healing in ulcerative colitis has been associated with decreased need for corticosteroids,²¹ decreased hospitalization rates,²²⁻²⁴ sustained clinical remission,²⁵ decreased colectomy^{21,22,24,25} and decreased risk of colorectal cancer.²⁶

Many different endoscopic indices for ulcerative colitis have been used in clinical trials (see [Supplementary information S1 \(table 1\) online](#)). This Review focuses on

the endoscopic indices that we, the authors, feel are best used in clinical practice: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)^{8,9} and Mayo Clinic endoscopy subscore.¹¹

The UCEIS is the only validated endoscopic index in ulcerative colitis (see [Supplementary information S2 \(table 5\) online](#)),^{8,9} and was developed because of wide inter-observer variation in endoscopic assessment of disease activity when using previously published endoscopic indices.⁴ The UCEIS is simple to use in clinical practice, as all it requires is the endoscopist to grade vascular pattern, bleeding and erosions or ulceration, which then allows a total score from 0 to 8 to be calculated. Disadvantages of the UCEIS are that extent of disease is not documented (as only the worst affected area is scored), there is no definition of mucosal healing, nor are there any validated thresholds for mild, moderate or severe disease. Use of the UCEIS has been shown to reduce inter-observer variation,^{8,27} and its responsiveness will be defined by its use in clinical trials of ulcerative colitis that are currently in progress.²⁸ We encourage its use in clinical practice so that there is a uniform language for describing disease activity. The remission target is a UCEIS total score of ≤ 1 .³

The Mayo Clinic endoscopy subscore has not been formally validated, however it has been the standard for assessing disease activity in adult clinical trials where endoscopic assessment is mandated by the FDA.¹⁶ The subscore has four components, each with a maximum score of 3 (see [Supplementary information S2 \(table 6\) online](#)).² Overlap in the features of the different levels contributes to inter-observer variation; moreover, the index [\[Au:OK?\]](#) does not take into account extent

of disease and there is no validated definition of mucosal healing. The value of using the Mayo Clinic Score in clinical practice simply reflects familiarity among practitioners. The remission target is a Mayo Clinic endoscopy subscore of ≤ 1 , reflecting the use of this threshold as an outcome measure in clinical trials, its association with a lower colectomy rate during follow-up, and recommendation by a group of international specialists.³

[H3] Histological assessment of disease activity.

Substantial disparity exists between histological and endoscopic disease activity assessment in ulcerative colitis.⁵ Microscopic inflammation can persist despite the appearance of endoscopically healed colonic mucosa, representing a harbinger of residual active disease.^{29,30} Accordingly, observational studies have shown that persistent histological inflammation in ulcerative colitis is associated with an increased risk of clinical relapse, hospitalization, colectomy and colorectal neoplasia.³⁰⁻³³ Histological remission is not yet recommended as a target of treatment in either clinical trials or practice³, however the FDA are considering documentation of patient histological disease activity at trial inclusion and as an outcome measure in clinical trials.⁵ Histological healing represents 'complete' remission in ulcerative colitis, and given its association with improved patient outcomes and reduced disease-related complications, is likely to be a future therapeutic target in clinical practice.⁵

There are 26 histological activity indices in ulcerative colitis, only two of which are validated (see [Supplementary information S1 \(table 1\) online](#)).^{6,34} As a consequence, no gold standard exists for assessing histological disease activity, nor for defining

1 histological remission, in patients with ulcerative colitis. The operating characteristics
2 of any histological scoring system in ulcerative colitis depend on the number, quality
3 and distribution of colonic biopsy samples taken, as well as the histological features
4 incorporated.^{5,35,36} Histological features with the highest intra-observer and inter-
5 observer agreement are erosion or ulceration, and the presence and density of
6 lamina propria neutrophil infiltrates.^{36,37} Basal plasmacytosis has been associated
7 with increased risk of ulcerative colitis relapse,³⁰ but concordance between reporting
8 histopathologists is poor.^{36,37}

9
10 Until 2015, the Riley Score (see [Supplementary information S2 \(table 7\) online](#)),³⁸
11 and the Geboes Score (see [Supplementary information S2 \(table 8\) online](#)) were the
12 most useful histological indices in patients with ulcerative colitis.³⁹ These scoring
13 systems are widely used, and each has been shown to predict clinical relapse in
14 patients with endoscopically quiescent disease.^{30,38,40} However, the operating
15 characteristics of the scores in assessing the intended histological parameters are
16 only partially validated and each includes histological features, such as crypt
17 destruction, crypt architectural changes, and lamina propria eosinophils that lack
18 reproducibility.^{36,37} Two new, validated indices have been developed for use in
19 patients with ulcerative colitis: the Nancy Index (see [Supplementary information S2](#)
20 [\(table 9\) online](#)),⁶ and the Roberts Histopathology Index (RHI; see [Supplementary](#)
21 [information S2 \(table 10\) online](#)).³⁴ Of these indices, the Nancy Index is our
22 recommendation for use in clinical practice, because of its simplicity, reproducibility
23 and ease of use, whereas the RHI will probably be preferred for clinical trials, owing
24 to well-defined responsiveness.

The Nancy Index and the RHI are validated, reproducible and responsive.^{6,34} The Nancy Index has three histological descriptors (the presence of ulceration, the severity of acute inflammatory infiltrate and the severity of chronic inflammatory infiltrate) defining five grades of activity (grade 0, least severe disease, to grade 4, most severe disease) in a weighted scoring algorithm (presence of ulceration defines the most severe disease).⁶ The RHI incorporates four histological descriptors (severity of chronic inflammatory infiltrate, the number of lamina propria neutrophils, the number of neutrophils in the epithelium and the severity of erosions or ulceration), each of which is objectively graded between 0 and 3. Using data from a phase II trial of vedolizumab, this index has been shown to be responsive to disease activity change, and is probably a useful tool for clinical trials.⁴¹

[H3]Radiological assessment of disease activity.

Imaging techniques are adjunctive to endoscopic assessment of disease activity in ulcerative colitis, and resolution of radiologic abnormalities in UC is not considered a treatment target in clinical practice.^{3,42}

Abdominal radiography is indicated in patients with severe ulcerative colitis to assess the extent of faecal residue, colonic dilatation or mucosal islands (areas of preserved colonic mucosa amidst denuded ulcerated mucosa).⁴² Features on plain abdominal radiography, in particular toxic megacolon (colonic dilatation >5.5 cm), assist with prognostication of patients with severe colitis, and can guide management toward colectomy.^{42,43} Plain abdominal radiography has no role in ulcerative colitis disease activity assessment outside of the acute setting, as it lacks sensitivity in evaluating

1 mild–moderate grades of disease severity, but might identify proximal constipation
2 as a cause of refractory distal disease.^{42,44}

3
4 Cross-sectional imaging in ulcerative colitis is predominantly performed to assess
5 complications of disease, to exclude small bowel inflammation and Crohn's disease
6 as a differential diagnosis and to assess colonic disease when stenosis or severe
7 comorbidities limit the utility of colonoscopy.^{17,42} CT is associated with radiation
8 exposure and has little role in assessing disease activity in ulcerative colitis;
9 inflammation as assessed by CT correlates only moderately with endoscopic colonic
10 inflammation (sensitivity 74%),⁴⁵ and use of CT infrequently leads to a change in
11 clinical management.⁴⁶

12
13 MRI and bowel ultrasonography demonstrate good sensitivity for evaluating disease
14 activity and extent in ulcerative colitis without associated ionizing radiation, and
15 represent the most useful techniques for assessing luminal disease activity in
16 ulcerative colitis when patient or disease-related factors render endoscopic
17 examination infeasible.⁴² (see [Supplementary information S1 \(table 1\) online](#)). Two
18 scoring systems have been described for the assessment of colonic inflammation in
19 ulcerative colitis with MRI, one with and one without bowel preparation.^{47,48} A
20 simplified magnetic resonance colonography index (MRC-S), based on four
21 radiological features (gadolinium contrast uptake, presence of oedema,
22 lymphadenopathy, and presence of the comb sign (hypervascularity of the
23 mesentery)), correlates significantly with endoscopy as a reference standard
24 ($r = 0.81$, $P < 0.001$) (see [Supplementary information S2 \(table 11\) online](#)).⁴⁷ The
25 presence of one of these features (MRC-S ≥ 1) has high sensitivity and specificity for

1 active disease (87% and 88% respectively). Using MRI and diffusion-weighted
2 imaging (technique used to evaluate cellular movement within a tissue voxel) without
3 bowel preparation, a segmental MRI score (MR-score-S) of >1, demonstrated a
4 sensitivity and specificity of 89% and 86% for active disease (see [Supplementary](#)
5 [information S2 \(table 12\) online](#)).⁴⁸ The MR-score-S is calculated from six
6 radiological features, including the presence of intestinal ulceration, parietal oedema,
7 and differentiation between bowel wall layers.. The MRC-S might be a simpler score
8 to use in clinical practice as it includes fewer variables, however the MR-score-S is
9 benefited by not requiring bowel preparation

10
11 Disease assessment by bowel ultrasonography has been shown to correlate with
12 colonic inflammation in ulcerative colitis, although performance is operator-
13 dependent and might not be generalizable.⁴² An ultrasonography scoring system
14 proposed by Parente *et al.*⁴⁹ is useful in clinical practice and incorporates
15 measurement of colonic wall thickness with the degree of intramural blood flow
16 ([Supplementary information S2 \(table 13\) online](#)).^{49,50} This score is concordant with
17 the severity of endoscopically assessed inflammation in moderate to severe
18 ulcerative colitis (weighted kappa 0.76–0.90), and is responsive to disease activity
19 change after steroid therapy, predicting disease outcomes at 15 months.⁴⁹ Bowel
20 ultrasonography is a helpful adjunct to endoscopy in ulcerative colitis, as it is a
21 cheap, noninvasive, and non-irradiating means of monitoring disease activity and
22 extent, and is convenient to patients given that it can [\[Au:OK?\]](#) be readily performed
23 in the clinical setting. ⁵¹ However, expertise in bowel ultrasonography might be
24 limited in many centres, and MRI might be the preferred imaging modality.

[H3]Biomarkers to assess disease activity.

Biomarkers are a useful adjunct to endoscopy for assessing disease activity in ulcerative colitis,³ in that they are non-invasive and yet provide objective evidence of inflammation beyond clinical assessment alone. The most useful biomarkers in ulcerative colitis are plasma levels of C-reactive protein (CRP) and faecal calprotectin.

CRP is a useful marker in clinical practice for predicting disease outcomes at the time of diagnosis of ulcerative colitis, and in patients with severe ulcerative colitis. Plasma CRP levels have been shown to predict the risk of colectomy in patients with ulcerative colitis.⁵²⁻⁵⁷ The Oxford criteria (more than eight stools per day or 3–8 stools per day and plasma CRP concentration >45 mg/l (>428.6 nmol/l)) predicts an 85% risk of colectomy during the period of that hospital admission after 3 days of intravenous corticosteroid therapy for acute severe colitis ([Supplementary information S2 \(table 14\) online](#)).⁵⁵ These criteria provide an indication of the need for medical rescue therapy, such as cyclosporine or infliximab.¹ A scoring system involving plasma CRP levels, extent of disease, and serum hemoglobin levels at the time of diagnosis of UC, has been shown to predict the risk of acute severe colitis within 3 years.^{58,59} Although a reduction in plasma CRP level has been shown to correlate with treatment response, CRP concentration is less useful in quiescent, mild, or moderately active ulcerative colitis, as it correlates weakly with endoscopic disease activity.⁶⁰

Faecal calprotectin level is a useful noninvasive tool for monitoring disease activity over time. This biomarker has been shown to predict persistent inflammation⁶¹⁻⁶³ and

1 risk of relapse⁶⁴⁻⁶⁸ in patients with ulcerative colitis, and is responsive to up-titration
2 of therapy.⁶⁹ However, a single faecal calprotectin cut-off value to predict
3 endoscopically assessed disease remission is not credible, because a broad range
4 of cut-off values have been described (ranging from <50 µg/g to <250 µg/g), mostly
5 with only moderate sensitivity and specificity for disease activity.^{70,71} Faecal
6 calprotectin level varies widely between stools on a daily basis in patients with active
7 ulcerative colitis,⁷² and readings can be influenced by variability inherent in the
8 assay.⁷³ The clinical utility of faecal calprotectin levels for an individual patient lies in
9 monitoring the change of this biomarker over time (Δ faecal calprotectin); rising faecal
10 calprotectin levels prompt endoscopic evaluation and guide therapy. No useful
11 disease activity scoring system based upon faecal calprotectin levels exists.

13 **[H3] QOL in ulcerative colitis.**

14 Measurement of QOL is important in the assessment of IBD because it evaluates the
15 patient's social and emotional well-being, behaviour and attitudes, and (to some
16 extent) physical disease-related symptoms. QOL assessments are now an important
17 component of medical decision-making, as improving QOL is the ultimate goal of
18 therapy and value-based health care **[Au: Sentence OK?]** An international working
19 group is developing a standard set of measures in IBD (www.ichom.org), and are
20 due to report in late 2016.. Nevertheless, most disease-specific QOL indices (such
21 as the IBDQ⁷⁴) for IBD are lengthy and time-consuming and this often precludes their
22 use in clinical settings.. The challenge is to find a measure of QOL that is fast to
23 complete, valid, internally reliable, reproducible, responsive and acceptable to
24 patients.

1 The questionnaire that we recommend for use in clinical practice is the IBD-
2 Control.(Supplementary information S2 (table 15) online). ⁷⁵ IBD-Control is the first
3 patient-related outcome measure to capture disease control from the patient's
4 perspective, using a simple set of generic terms applicable to both ulcerative colitis
5 and Crohn's disease. Summary scores show strong validity versus more complex
6 QOL questionnaires, disease activity scores and Global Physician Assessment.⁷⁵ A
7 limited version, IBD-Control 8, includes the questionnaire elements 1a, 1b and 3a–3f,
8 with the total score being calculated as follows: the 'worst' response is scored 0
9 (being either a 'Yes' or 'No' depending on the question), 'not sure' is scored 1, and
10 the 'best' response (being either a 'Yes' or 'No' depending on the question) is scored
11 2. For IBD-Control-8, if all response are favourable, the maximum score is 16,
12 equating to the best disease control [\[Au:Edit of this section OK?\]](#) . This
13 questionnaire is free to use and (unlike the Short Inflammatory Bowel Disease
14 Questionnaire (SIBDQ)) not subject to license. Its simplicity, the fact that it is
15 completed by patients, and that it has been adopted by international groups (ICHOM
16 and the UK IBD Registry) are other advantages.

17
18 Other QOL questionnaires used in clinical practice include the SIBDQ⁷⁶ (see
19 Supplementary information S2 (table 16)) and the Crohn's Ulcerative Colitis
20 Questionnaire-8 (CUCQ-8)⁷⁷ (see Supplementary information S2 (table 17)). These
21 short questionnaires (the SIBDQ has 10 questions and the CUCQ-8 has eight
22 questions) explain >95% of the variance of their respective 32 question versions (the
23 IBDQ and the CUCQ-32)

1 The SIBDQ gives results similar to the full 32-item IBDQ,⁷⁴ is widely accepted and
2 has been validated in different populations.⁷⁶ Scores generated by this index range
3 from 10–70, which correspond to poor-to-good QOL, respectively. This questionnaire
4 is reproducible and responsive to changes in disease severity⁷⁸, but there is a
5 licensing fee attached to its use.

6
7 The CUCQ-8, developed from the CUCQ-32, was designed for use in clinical
8 practice, both for patients with stable disease as well as those with acute IBD.
9 Scores range from 0–8, which correspond to good to poor QOL, notably the opposite
10 way around to the SIBDQ and IBD-Control. The CUCQ-8 requires no licensing fee
11 for its use and is the only QOL index that has been used as a primary end-point in a
12 randomized clinical trial (CONSTRUCT) in ulcerative colitis.⁷⁹

13
14

[H1] Crohn's disease

[H3]Clinical assessment of disease activity.

The Crohn's Disease Activity Index (CDAI, see Supplementary information S2 (table 18)) is the most commonly used tool for assessing disease response to treatment in Crohn's disease clinical trials.⁸⁰ However, calculation of the CDAI is complex and involves eight items, including haematocrit, physical examination (abdominal examination and weight measurement) and a 7-day patient diary (to record number of soft stools, abdominal pain and general well-being), so it is rarely used in clinical practice. Inter-observer variability between CDAI scores is high, even among experienced physicians.⁸¹ The remission target is a CDAI <150.³

The Harvey-Bradshaw Index (HBI)⁸² (see Supplementary information S2 (table 19) online) is simpler to use than the CDAI and this makes data collection easier⁸³; moreover, scores from this index have been shown to correlate closely with CDAI scores.⁸³ The HBI has five variables (including general well-being, severity of abdominal pain, number of liquid stools, presence of abdominal mass and presence of complications) and items are scored based upon the previous day, so it does not require prospective 7-day data collection. The remission target for this index is an HBI score ≤ 4 .³

The CDAI is not an accurate instrument to assess the activity of perianal Crohn's disease or Crohn's disease with other fistulae, because the presence of perianal disease or other fistulae (which can be terribly disabling for the patient) only accounts for a small proportion of the total score.. The perianal Crohn's disease activity index (PDAI)⁸⁴ is currently the gold standard for evaluating the severity of

perianal disease (see Supplementary information S2 (table 20) online). This index comprises five items: discharge; pain; restriction of sexual activity; type of perianal disease; degree of induration. Discharge, pain and degree of induration seem to be more commonly used in clinical practice.

[H3]Endoscopic assessment of disease activity.

In contrast to ulcerative colitis, mucosal healing in Crohn's disease might reasonably be considered a minimal (rather than the ultimate) therapeutic goal, because Crohn's disease is transmural . The benefits of achieving mucosal healing include decreased need for corticosteroids, decreased hospitalization, sustained clinical remission and decreased need for surgery.^{21,23,24}

Complete resolution of all endoscopically visible ulcers is a simple definition of mucosal healing for clinical practice and has been recommended by international consensus bodies.⁸⁵ Nevertheless, the binomial definition (presence or absence of ulcers) is currently unvalidated, difficult to achieve and crude, because it does not allow quantification of improvement of mucosal inflammation.⁸⁶

Validated endoscopic indices have been developed for the assessment of Crohn's disease activity (see Supplementary information S1 (table 2) online). The Crohn's Disease Activity Index of Severity (CDEIS)⁸⁷ is the most commonly used tool in clinical trials, whereas the Simple Endoscopic Score for Crohn's Disease (SES-CD)⁸⁸ is a slightly simplified version of the same index. Rutgeerts' Post-operative Endoscopic Index⁸⁹ is used for estimating the risk of disease recurrence after ileocolic resection for Crohn's disease.

1 The CDEIS examines four endoscopic variables (the presence of deep ulceration,
2 superficial ulceration, the length of ulcerated mucosa and the length of diseased
3 mucosa) in each of the following locations: rectum, sigmoid and left colon, transverse
4 colon, right colon and ileum (see [Supplementary information S2 \(table 21\)](#) and
5 [Supplementary information S3 \(file\) online](#)). Although the CDEIS is a reproducible
6 and validated index, it is complex, requiring over 30 entries to reach the final score.⁸⁷
7 As with all indices, implementation requires both training and experience, but the
8 complexity of the CDEIS makes it cumbersome to use in clinical practice. The
9 remission target is a total CDEIS score of <3.³

11 The SES-CD (see [Supplementary information S2 \(table 22\) online](#)) correlates well
12 with the CDEIS, but is only slightly less complex, requiring over 20 entries to
13 complete the total score, and therefore also being difficult to complete in routine
14 clinical practice..⁸⁸ Endoscopic features (ulcer size, extent of ulcerated surfaces,
15 extent of surfaces with any other lesions and stenosis) are scored from 0 to 3
16 depending on severity or extent in each of the five colorectal locations assessed by
17 the CDEIS. An SES-CD score of 0 equates to absence of ulcers.

19 Rutgeerts' Post-operative Endoscopic Index (see [Supplementary information S2](#)
20 [\(table 23\) online](#)) determines the severity of endoscopic disease recurrence at the
21 anastomosis and in the neo-terminal ileum after ileocolic resection.^{89,90} This index
22 consists of 5 grades of increasing disease recurrence severity, between i0 and i4, as
23 assessed by the number and nature of ulcers in the distal ileum. The Post-operative
24 Endoscopic Index has gained popularity because its assessment of disease
25 recurrence predicts symptom recurrence. The remission target is a grade <i2.³

For endoscopic reporting of Crohn's disease activity in clinical practice, we recommend using the SES-CD, or at the very least reporting, for each bowel section, the presence or absence of ulcers, stenosis and the proportion of surface area affected. For postoperative assessment of disease recurrence following ileocolic resection, we recommend Rutgeerts' score.

[H3]Histological assessment of disease activity.

Histological disease activity assessment in Crohn's disease is difficult because inflammation is discontinuous, transmural and can exist beyond the reach of the endoscope.^{5,35} Targeted mucosal biopsies can be used in an attempt to limit sampling error, but transmural inflammation can only be assessed in specimens obtained during surgical resection. Thus, histological scoring systems for mucosal biopsy samples are challenging both to develop and to use in practice.⁹¹ Nevertheless, microscopic inflammation can persist in biopsy samples from tissue that appears quiescent when observed endoscopically,^{29,92,93} and some limited evidence suggests that presence of microscopic inflammation is associated with increased rates of clinical relapse, stricture formation and surgery.²⁹

Several histological scoring systems have been proposed for assessing Crohn's disease activity (see [Supplementary information S1 \(table 2\) online](#)), the best known of which are the Colonic and Ileal Global Histologic Disease Activity Scores (CGHAS and IGHAS) (see [Supplementary information S2 \(table 24\) online](#)).^{91,94,95} Due to the complexity of these scoring systems and lack of evidence correlating histological disease activity with disease outcomes in Crohn's disease, we do not recommend

1 routine use of such scoring in clinical practice. Rather, the presence of histological
2 inflammation in endoscopically quiescent disease should caution against de-
3 escalation of therapy.⁵

4 5 **[H3]Radiological assessment of disease activity.**

6 Given that transmural inflammation in Crohn's disease can extend beyond the reach
7 of endoscopy, imaging has an important role in assessing disease activity.⁴² Imaging
8 also enables evaluation of the complications of Crohn's disease, including stricturing
9 disease, fistulae and abscesses.⁹⁶ MRI is the preferred modality for assessing
10 extraluminal complications of Crohn's disease and the presence and severity of
11 perianal fistulae in particular. MRI and ultrasonography are the preferred modalities
12 for assessing luminal disease activity and strictures in Crohn's disease.⁴²

13
14 Although the overall accuracy of CT, ultrasonography and MRI for assessing luminal
15 disease activity in Crohn's disease is similar,^{42,96} radiation exposure limits the use of
16 CT, which is particularly relevant to younger patients who might be exposed to a
17 substantial cumulative radiation dose over their disease course. CT is therefore not
18 the first-choice imaging technique for assessing disease activity in Crohn's disease;
19 when MRI and ultrasonography are unavailable, low-dose CT can be an
20 alternative.⁹⁷ Plain film radiography and barium contrast studies now have little role
21 in Crohn's disease, due to their limited sensitivity for assessing activity in comparison
22 to MRI, CT and ultrasonography.⁴²

23
24 Intestinal MRI requires rapid image acquisition and luminal distension for accurate
25 assessment of disease distribution and activity, which can be achieved with a neutral

1 contrast agent delivered via enterography or enteroclysis.⁹⁸ Amongst the available
2 scoring systems (see [Supplementary information S1 \(table 2\) online](#)), the Magnetic
3 Resonance Index of Activity (MaRIA) is best-validated for assessment of disease
4 activity in CD and we recommend its use in clinical practice (see [Supplementary](#)
5 [information S2 \(table 25\) online](#)).^{99,100} The MaRIA correlates well with CDEIS scores
6 assessed by ileocolonoscopy ($r = 0.83$, $P < 0.001$),⁹⁹ and has been shown to be
7 reliable in assessing disease response to therapy in Crohn's disease (90% accuracy
8 for detecting ulcer healing and 83% accuracy for detecting endoscopic remission as
9 assessed using CDEIS).¹⁰¹ Although MRI is expensive in comparison to other
10 imaging modalities, the technique is cost-effective compared with CT in patients
11 younger than 50 years old, based on quality-adjusted life-year data factoring in
12 radiation exposure.¹⁰²

13
14 MRI is a widely used and accurate tool to assess the presence and severity of
15 perianal fistulizing disease⁴². The Van Assche MRI-based score for assessing the
16 severity of perianal Crohn's disease,¹⁰³ based on the classification of perianal fistula
17 developed at St. Mark's Hospital, Harrow, UK¹⁰⁴, is useful for formal assessment of
18 response of fistulizing disease to therapy (see [Supplementary information S2 \(table](#)
19 [26\)](#)). The score incorporates criteria relating to the local extension of fistulae, as well
20 as active inflammation, and it demonstrates good inter-observer agreement and
21 responsiveness following anti-TNF therapy.¹⁰³ The score is useful for clinical trials,
22 but has less utility in clinical practice due to its relative complexity compared with
23 other scores.

Doppler ultrasonography is helpful in assessing disease activity, based on intestinal wall thickness and intensity of flow.¹⁰⁵⁻¹⁰⁷ Although there are several scoring systems for ultrasonographic assessment of disease activity (see [Supplementary information S1 \(table 2\) online](#)), the most widely used of which is the Limberg Score (see [Supplementary information S2 \(table 27\) online](#)),¹⁰⁸ none of these indices have been validated. Small studies ($n = 24-110$) have shown that ultrasonography is responsive to improvements in disease activity following therapy,¹⁰⁹⁻¹¹² and might be useful for disease monitoring after surgical resection.^{113,114} Point-of-care ultrasonography has also been shown to influence clinical decision-making, particularly when patients are asymptomatic but ultrasonography reveals evidence of active disease.¹¹⁵ Despite promising data, the use of ultrasonography remains limited by the availability of an experienced bowel sonographer. Outside Europe, ultrasonography has been less commonly used, with cross-sectional imaging (CT and MRI) favoured for its reproducible protocols and capacity for archival images. However, as clinician awareness of the imperative for close monitoring of IBD disease activity as a part of a 'treat to target' management strategy grows, ultrasonography is becoming increasingly appealing as a cheap and noninvasive tool, and its use is burgeoning in countries such as Australia.⁵¹

[H3]Biomarkers to assess disease activity.

Biomarkers are a noninvasive adjunct to endoscopy and cross-sectional imaging for monitoring disease activity in Crohn's disease.³ Plasma levels of CRP and faecal calprotectin are the most useful biomarkers in clinical practice.

1 An improvement in plasma CRP levels (that is, a reduced plasma concentration of
2 CRP) has been shown to correlate with a clinical therapeutic response in Crohn's
3 disease.¹¹⁶⁻¹²² An elevated plasma CRP level predicts clinical relapse in Crohn's
4 disease,^{123,124} in both asymptomatic patients,¹²⁵ as well as following withdrawal of
5 therapy.¹²⁶⁻¹²⁸ Higher plasma CRP levels prior to treatment have been shown to
6 predict an increased likelihood of maintenance of remission following anti-TNF
7 therapy.¹²⁹ However, CRP level correlates only modestly with endoscopic disease
8 activity in Crohn's disease^{70,71,130-133}, and a normal plasma CRP concentration has
9 been reported in patients with active disease, particularly those with predominantly
10 ileal rather than predominantly colonic pathology.¹³⁴⁻¹³⁶ The converse is also true, as
11 an elevated CRP level does not always correlate with active disease.¹³⁰ Plasma CRP
12 concentration is therefore not a target of therapy, but rather a tool to monitor
13 inflammation to guide the necessity of radiological or endoscopic activity
14 assessment.

15
16 Faecal calprotectin level has been shown to correlate with endoscopic and MRI-
17 based assessment of disease activity in Crohn's disease,^{131,137-139} and to predict
18 disease relapse.^{65,68,140,141} Levels of faecal calprotectin are also useful in monitoring
19 disease activity following initiation of therapy,¹²² as well as in the post-operative
20 Crohn's disease setting.^{136,142} However, faecal calprotectin concentration is less
21 accurate for ileal than colonic disease, and can be normal even in the presence of
22 large ulcers.¹⁴³ Faecal calprotectin level cut-off values for predicting remission vary
23 widely between studies (from <50 µg/g to <250 µg/g) and are only moderately
24 predictive for individual patients,⁷¹ unless a stringent cut-off value is used (such as
25 <50 µg/g), which comes at the expense of sensitivity or unnecessary investigations.

1 Thus, as for ulcerative colitis, it seems that the change in faecal calprotectin level,
2 rather than the absolute level in an individual patient, is best used in clinical practice
3 to aid treatment decision-making.

4 5 **[H3] QOL**

6 The three QOL questionnaires that we recommend for use in clinical practice and the
7 rationale behind these choices are the same as those used in ulcerative colitis: either
8 IBD-Control⁷⁵ (see [Supplementary information S2 \(table 15\) online](#)), the SIBDQ⁷⁶
9 (see [Supplementary information S2 \(table 16\) online](#)) or the CUCQ-8⁷⁷ (see
10 [Supplementary information S2 \(table 17\) online](#)).

[H1]Conclusions

The overarching goal of therapy in IBD is to modify the disease course to improve QOL and avoid disability, whilst balancing the risks associated with therapy.^{144,145} To reach this goal, therapy must be directed to achieve resolution of both objective inflammation and clinical symptoms, as well as normalization of QOL. This 'treat to target' approach requires a clinician to look beyond clinical symptoms and to assess disease activity as objectively as possible. This method enables a composite appraisal of the measurable burden of inflammation, the burden of disease on the patient and the cumulative complications of disease over its course.¹⁴⁵

Despite the disparity between clinical and objective measures of inflammation in IBD, both are important when assessing disease activity. The objective burden of inflammation denotes risk of negative disease outcomes in IBD, whilst clinicians realize that symptoms and QOL are most important to patients. Amongst the confusing myriad of disease activity indices within each domain of assessment, this Review has collected and appraised the most practical and relevant indices for clinical practice, augmented by supplementary tables to provide a comprehensive overview. Current indices need to be validated according to well-established statistical criteria. The metrics will help with clinical decision-making and encourage physicians to strive for appropriate treatment targets that can be expected to improve outcomes for people with IBD.

References

- 1 Dignass, A. *et al.* Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *Journal of Crohn's & colitis* **6**, 991-1030, doi:10.1016/j.crohns.2012.09.002 (2012).
- 2 Dignass, A. *et al.* The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. *Journal of Crohn's & colitis* **4**, 28-62, doi:10.1016/j.crohns.2009.12.002 (2010).
- 3 Peyrin-Biroulet, L. *et al.* Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *The American journal of gastroenterology* **110**, 1324-1338, doi:10.1038/ajg.2015.233 (2015).
- 4 Walsh, A. J. *et al.* Comparing disease activity indices in ulcerative colitis. *Journal of Crohn's & colitis* **8**, 318-325, doi:10.1016/j.crohns.2013.09.010 (2014).
- 5 Bryant, R. V., Winer, S., Travis, S. P. & Riddell, R. H. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. *Journal of Crohn's & colitis* **8**, 1582-1597, doi:10.1016/j.crohns.2014.08.011 (2014).
- 6 Marchal-Bressenot, A. *et al.* Development and validation of the Nancy histological index for UC. *Gut*, doi:10.1136/gutjnl-2015-310187 (2015).
- 7 Travis, S. P. *et al.* Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut* **63**, 433-441, doi:10.1136/gutjnl-2012-304258 (2014).
- 8 Travis, S. P. *et al.* Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). *Gut* **61**, 535-542, doi:10.1136/gutjnl-2011-300486 (2012).
- 9 Travis, S. P. *et al.* Reliability and initial validation of the ulcerative colitis endoscopic index of severity. *Gastroenterology* **145**, 987-995, doi:10.1053/j.gastro.2013.07.024 (2013).
- 10 Walmsley, R. S., Ayres, R. C., Pounder, R. E. & Allan, R. N. A simple clinical colitis activity index. *Gut* **43**, 29-32 (1998).
- 11 Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *The New England journal of medicine* **317**, 1625-1629, doi:10.1056/nejm198712243172603 (1987).
- 12 Sandborn, W. J. *et al.* Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Alimentary pharmacology & therapeutics* **17**, 1355-1364 (2003).
- 13 Turner, D. *et al.* Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* **133**, 423-432, doi:10.1053/j.gastro.2007.05.029 (2007).
- 14 Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. *British medical journal* **2**, 1041-1048 (1955).
- 15 Turner, D. *et al.* A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* **7**, 1081-1088, doi:10.1016/j.cgh.2009.06.024 (2009).

- 1 16 D'Haens, G. *et al.* A review of activity indices and efficacy end points for clinical trials
2 of medical therapy in adults with ulcerative colitis. *Gastroenterology* **132**, 763-786,
3 doi:10.1053/j.gastro.2006.12.038 (2007).
- 4 17 Dignass, A. *et al.* Second European evidence-based consensus on the diagnosis and
5 management of ulcerative colitis part 1: definitions and diagnosis. *Journal of Crohn's*
6 *& colitis* **6**, 965-990, doi:10.1016/j.crohns.2012.09.003 (2012).
- 7 18 Dinesen, L. C. *et al.* The pattern and outcome of acute severe colitis. *Journal of*
8 *Crohn's & colitis* **4**, 431-437, doi:10.1016/j.crohns.2010.02.001 (2010).
- 9 19 Neurath, M. F. & Travis, S. P. Mucosal healing in inflammatory bowel diseases: a
10 systematic review. *Gut* **61**, 1619-1635, doi:10.1136/gutjnl-2012-302830 (2012).
- 11 20 Sandborn, W. J. *et al.* A review of activity indices and efficacy endpoints for clinical
12 trials of medical therapy in adults with Crohn's disease. *Gastroenterology* **122**, 512-
13 530 (2002).
- 14 21 Frosli, K. F., Jahnsen, J., Moum, B. A. & Vatn, M. H. Mucosal healing in inflammatory
15 bowel disease: results from a Norwegian population-based cohort. *Gastroenterology*
16 **133**, 412-422, doi:10.1053/j.gastro.2007.05.051 (2007).
- 17 22 Ardizzone, S. *et al.* Randomised controlled trial of azathioprine and 5-aminosalicylic
18 acid for treatment of steroid dependent ulcerative colitis. *Gut* **55**, 47-53,
19 doi:10.1136/gut.2005.068809 (2006).
- 20 23 Rutgeerts, P. *et al.* Scheduled maintenance treatment with infliximab is superior to
21 episodic treatment for the healing of mucosal ulceration associated with Crohn's
22 disease. *Gastrointestinal endoscopy* **63**, 433-442; quiz 464,
23 doi:10.1016/j.gie.2005.08.011 (2006).
- 24 24 Schnitzler, F. *et al.* Mucosal healing predicts long-term outcome of maintenance
25 therapy with infliximab in Crohn's disease. *Inflammatory bowel diseases* **15**, 1295-
26 1301, doi:10.1002/ibd.20927 (2009).
- 27 25 Colombel, J. F. *et al.* Early mucosal healing with infliximab is associated with
28 improved long-term clinical outcomes in ulcerative colitis. *Gastroenterology* **141**,
29 1194-1201, doi:10.1053/j.gastro.2011.06.054 (2011).
- 30 26 Rutter, M. *et al.* Severity of inflammation is a risk factor for colorectal neoplasia in
31 ulcerative colitis. *Gastroenterology* **126**, 451-459 (2004).
- 32 27 Corte, C. J. *et al.* Association between the Ulcerative Colitis Endoscopic Index of
33 Severity (UCEIS) and outcomes in acute severe ulcerative colitis. *Journal of Crohn's &*
34 *colitis*, doi:10.1093/ecco-jcc/jjv047 (2015).
- 35 28 Ikeya, K. *et al.* The Ulcerative Colitis Endoscopic Index of Severity More Accurately
36 Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic
37 Score. *Journal of Crohn's & colitis*, doi:10.1093/ecco-jcc/jjv210 (2015).
- 38 29 Baars, J. E., Nuij, V. J., Oldenburg, B., Kuipers, E. J. & van der Woude, C. J. Majority of
39 patients with inflammatory bowel disease in clinical remission have mucosal
40 inflammation. *Inflammatory bowel diseases* **18**, 1634-1640, doi:10.1002/ibd.21925
41 (2012).
- 42 30 Bessissow, T. *et al.* Prognostic value of serologic and histologic markers on clinical
43 relapse in ulcerative colitis patients with mucosal healing. *The American journal of*
44 *gastroenterology* **107**, 1684-1692, doi:10.1038/ajg.2012.301 (2012).
- 45 31 Bitton, A. *et al.* Clinical, biological, and histologic parameters as predictors of relapse
46 in ulcerative colitis. *Gastroenterology* **120**, 13-20 (2001).

- 32 Bryant, R. V. *et al.* Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. *Gut*, doi:10.1136/gutjnl-2015-309598 (2015).
- 33 Gupta, R. B. *et al.* Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. *Gastroenterology* **133**, 1099-1105; quiz 1340-1091, doi:10.1053/j.gastro.2007.08.001 (2007).
- 34 Mosli, M. H. *et al.* Development and validation of a histological index for UC. *Gut*, doi:10.1136/gutjnl-2015-310393 (2015).
- 35 Magro, F. *et al.* European consensus on the histopathology of inflammatory bowel disease. *Journal of Crohn's & colitis* **7**, 827-851, doi:10.1016/j.crohns.2013.06.001 (2013).
- 36 Mosli, M. H. *et al.* Reproducibility of histological assessments of disease activity in UC. *Gut* **64**, 1765-1773, doi:10.1136/gutjnl-2014-307536 (2015).
- 37 Bressenot, A. *et al.* Comparing histological activity indexes in UC. *Gut*, doi:10.1136/gutjnl-2014-307477 (2014).
- 38 Riley, S. A., Mani, V., Goodman, M. J., Dutt, S. & Herd, M. E. Microscopic activity in ulcerative colitis: what does it mean? *Gut* **32**, 174-178 (1991).
- 39 Geboes, K. *et al.* A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. *Gut* **47**, 404-409 (2000).
- 40 Azad, S., Sood, N. & Sood, A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association* **17**, 194-198, doi:10.4103/1319-3767.80383 (2011).
- 41 Feagan, B. G. *et al.* Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. *The New England journal of medicine* **352**, 2499-2507, doi:10.1056/NEJMoa042982 (2005).
- 42 Panes, J. *et al.* Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *Journal of Crohn's & colitis* **7**, 556-585, doi:10.1016/j.crohns.2013.02.020 (2013).
- 43 Benchimol, E. I. *et al.* Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics. *The American journal of gastroenterology* **103**, 1524-1531, doi:10.1111/j.1572-0241.2008.01807.x (2008).
- 44 Allison, M. C. & Vallance, R. Prevalence of proximal faecal stasis in active ulcerative colitis. *Gut* **32**, 179-182 (1991).
- 45 Fletcher, J. G., Fidler, J. L., Bruining, D. H. & Huprich, J. E. New concepts in intestinal imaging for inflammatory bowel diseases. *Gastroenterology* **140**, 1795-1806, doi:10.1053/j.gastro.2011.02.013 (2011).
- 46 Yarur, A. J. *et al.* Predictive factors for clinically actionable computed tomography findings in inflammatory bowel disease patients seen in the emergency department with acute gastrointestinal symptoms. *Journal of Crohn's & colitis* **8**, 504-512, doi:10.1016/j.crohns.2013.11.003 (2014).
- 47 Ordas, I. *et al.* Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. *Gut* **62**, 1566-1572, doi:10.1136/gutjnl-2012-303240 (2013).
- 48 Oussalah, A. *et al.* Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. *Gut* **59**, 1056-1065, doi:10.1136/gut.2009.197665 (2010).

- 49 Parente, F. *et al.* Are colonoscopy and bowel ultrasound useful for assessing
response to short-term therapy and predicting disease outcome of moderate-to-
severe forms of ulcerative colitis?: a prospective study. *The American journal of*
gastroenterology **105**, 1150-1157, doi:10.1038/ajg.2009.672 (2010).
- 50 Parente, F. A., S.; Greco, S.; et al. Response to high-dose steroids of severe attacks of
ulcerative colitis may rely on bowel ultrasound instead of colonoscopy. A preliminary
study . *Gut* **55** A118 (2006).
- 51 Asthana, A. K. *et al.* Failure of gastroenterologists to apply intestinal ultrasound in
inflammatory bowel disease in the Asia-Pacific: a need for action. *Journal of*
gastroenterology and hepatology **30**, 446-452, doi:10.1111/jgh.12871 (2015).
- 52 Solem, C. A. *et al.* Correlation of C-reactive protein with clinical, endoscopic,
histologic, and radiographic activity in inflammatory bowel disease. *Inflammatory*
bowel diseases **11**, 707-712 (2005).
- 53 Osada, T. *et al.* Correlations among total colonoscopic findings, clinical symptoms,
and laboratory markers in ulcerative colitis. *Journal of gastroenterology and*
hepatology **23 Suppl 2**, S262-267, doi:10.1111/j.1440-1746.2008.05413.x (2008).
- 54 Turner, D. *et al.* Severe pediatric ulcerative colitis: a prospective multicenter study of
outcomes and predictors of response. *Gastroenterology* **138**, 2282-2291,
doi:10.1053/j.gastro.2010.02.047 (2010).
- 55 Travis, S. P. *et al.* Predicting outcome in severe ulcerative colitis. *Gut* **38**, 905-910
(1996).
- 56 Kumar, S., Ghoshal, U. C., Aggarwal, R., Saraswat, V. A. & Choudhuri, G. Severe
ulcerative colitis: prospective study of parameters determining outcome. *Journal of*
gastroenterology and hepatology **19**, 1247-1252, doi:10.1111/j.1440-
1746.2004.03486.x (2004).
- 57 Aceituno, M. *et al.* Steroid-refractory ulcerative colitis: predictive factors of response
to cyclosporine and validation in an independent cohort. *Inflammatory bowel*
diseases **14**, 347-352, doi:10.1002/ibd.20322 (2008).
- 58 Cesarini, M. C., G.; Ronnblom, A.; Santos, A.; Sjoberg, D.; Parkes, M.; Keshav, S.;
Travis, SPL. P079. Predicting the risk of acute severe colitis (ASC) at diagnosis of
Ulcerative Colitis (UC): external validation. *Journal of Crohn's & colitis* **9 Suppl 1**,
S117-118, doi:10.1093/ecco-jcc/jju027.197 (2015).
- 59 Henriksen, M. *et al.* C-reactive protein: a predictive factor and marker of
inflammation in inflammatory bowel disease. Results from a prospective population-
based study. *Gut* **57**, 1518-1523, doi:10.1136/gut.2007.146357 (2008).
- 60 Yoon, J. Y. *et al.* Correlations of C-reactive protein levels and erythrocyte
sedimentation rates with endoscopic activity indices in patients with ulcerative
colitis. *Digestive diseases and sciences* **59**, 829-837, doi:10.1007/s10620-013-2907-3
(2014).
- 61 Guardiola, J. *et al.* Fecal level of calprotectin identifies histologic inflammation in
patients with ulcerative colitis in clinical and endoscopic remission. *Clinical*
gastroenterology and hepatology : the official clinical practice journal of the
American Gastroenterological Association **12**, 1865-1870,
doi:10.1016/j.cgh.2014.06.020 (2014).
- 62 Yamaguchi, S. *et al.* Fecal calprotectin is a clinically relevant biomarker of mucosal
healing in patients with quiescent ulcerative colitis. *Journal of gastroenterology and*
hepatology, doi:10.1111/jgh.13061 (2015).

- 63 Theede, K. *et al.* Level of Fecal Calprotectin Correlates With Endoscopic and
64 Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative
65 Colitis. *Clinical gastroenterology and hepatology : the official clinical practice journal
66 of the American Gastroenterological Association* **13**, 1929-1936.e1921,
67 doi:10.1016/j.cgh.2015.05.038 (2015).
- 68 Yamamoto, T., Shiraki, M., Bamba, T., Umegae, S. & Matsumoto, K. Fecal calprotectin
69 and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis
70 during maintenance therapy. *International journal of colorectal disease* **29**, 485-491,
71 doi:10.1007/s00384-013-1817-3 (2014).
- 72 Gisbert, J. P. *et al.* Fecal calprotectin and lactoferrin for the prediction of
73 inflammatory bowel disease relapse. *Inflammatory bowel diseases* **15**, 1190-1198,
74 doi:10.1002/ibd.20933 (2009).
- 75 De Vos, M. *et al.* Consecutive fecal calprotectin measurements to predict relapse in
76 patients with ulcerative colitis receiving infliximab maintenance therapy.
77 *Inflammatory bowel diseases* **19**, 2111-2117, doi:10.1097/MIB.0b013e31829b2a37
78 (2013).
- 79 Molander, P. *et al.* Fecal calprotectin concentration predicts outcome in
80 inflammatory bowel disease after induction therapy with TNFalpha blocking agents.
81 *Inflammatory bowel diseases* **18**, 2011-2017, doi:10.1002/ibd.22863 (2012).
- 82 Molander, P. *et al.* Does fecal calprotectin predict short-term relapse after stopping
83 TNFalpha-blocking agents in inflammatory bowel disease patients in deep remission?
84 *Journal of Crohn's & colitis* **9**, 33-40, doi:10.1016/j.crohns.2014.06.012 (2015).
- 85 Osterman, M. T. *et al.* Mesalamine dose escalation reduces fecal calprotectin in
86 patients with quiescent ulcerative colitis. *Clinical gastroenterology and hepatology :
87 the official clinical practice journal of the American Gastroenterological Association*
88 **12**, 1887-1893.e1883, doi:10.1016/j.cgh.2014.03.035 (2014).
- 89 Falvey, J. D. *et al.* Disease activity assessment in IBD: clinical indices and biomarkers
90 fail to predict endoscopic remission. *Inflammatory bowel diseases* **21**, 824-831,
91 doi:10.1097/mib.0000000000000341 (2015).
- 92 Mosli, M. H. *et al.* C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for
93 Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease
94 Patients: A Systematic Review and Meta-Analysis. *The American journal of
95 gastroenterology* **110**, 802-819; quiz 820, doi:10.1038/ajg.2015.120 (2015).
- 96 Calafat, M. *et al.* High within-day variability of fecal calprotectin levels in patients
97 with active ulcerative colitis: what is the best timing for stool sampling?
98 *Inflammatory bowel diseases* **21**, 1072-1076, doi:10.1097/mib.0000000000000349
99 (2015).
- 100 Kristensen, V. *et al.* Prediction of endoscopic disease activity in ulcerative colitis by
101 two different assays for fecal calprotectin. *Journal of Crohn's & colitis* **9**, 164-169,
102 doi:10.1093/ecco-jcc/jju015 (2015).
- 103 Guyatt, G. *et al.* A new measure of health status for clinical trials in inflammatory
104 bowel disease. *Gastroenterology* **96**, 804-810 (1989).
- 105 Bodger, K., Ormerod, C., Shackcloth, D. & Harrison, M. Development and validation
106 of a rapid, generic measure of disease control from the patient's perspective: the
107 IBD-control questionnaire. *Gut* **63**, 1092-1102, doi:10.1136/gutjnl-2013-305600
108 (2014).

1 76 Irvine, E. J., Zhou, Q. & Thompson, A. K. The Short Inflammatory Bowel Disease
2 Questionnaire: a quality of life instrument for community physicians managing
3 inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse
4 Prevention Trial. *The American journal of gastroenterology* **91**, 1571-1578 (1996).
5 77 Alrubaiy, L. *et al.* Development of a short questionnaire to assess the quality of life in
6 Crohn's disease and ulcerative colitis. *Journal of Crohn's & colitis* **9**, 66-76,
7 doi:10.1093/ecco-jcc/jju005 (2015).
8 78 Jowett, S. L., Seal, C. J., Barton, J. R. & Welfare, M. R. The short inflammatory bowel
9 disease questionnaire is reliable and responsive to clinically important change in
10 ulcerative colitis. *The American journal of gastroenterology* **96**, 2921-2928,
11 doi:10.1111/j.1572-0241.2001.04682.x (2001).
12 79 Seagrove, A. C. *et al.* Randomised controlled trial. Comparison Of infliximab and
13 ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol
14 (CONSTRUCT). *BMJ open* **4**, e005091, doi:10.1136/bmjopen-2014-005091 (2014).
15 80 Best, W. R., Bectel, J. M., Singleton, J. W. & Kern, F., Jr. Development of a Crohn's
16 disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology*
17 **70**, 439-444 (1976).
18 81 Sands, B. E. & Ooi, C. J. A survey of methodological variation in the Crohn's disease
19 activity index. *Inflammatory bowel diseases* **11**, 133-138 (2005).
20 82 Harvey, R. F. & Bradshaw, J. M. A simple index of Crohn's-disease activity. *Lancet* **1**,
21 514 (1980).
22 83 Vermeire, S., Schreiber, S., Sandborn, W. J., Dubois, C. & Rutgeerts, P. Correlation
23 between the Crohn's disease activity and Harvey-Bradshaw indices in assessing
24 Crohn's disease severity. *Clinical gastroenterology and hepatology : the official*
25 *clinical practice journal of the American Gastroenterological Association* **8**, 357-363,
26 doi:10.1016/j.cgh.2010.01.001 (2010).
27 84 Irvine, E. J. Usual therapy improves perianal Crohn's disease as measured by a new
28 disease activity index. McMaster IBD Study Group. *Journal of clinical*
29 *gastroenterology* **20**, 27-32 (1995).
30 85 D'Haens, G. R. *et al.* Endpoints for clinical trials evaluating disease modification and
31 structural damage in adults with Crohn's disease. *Inflammatory bowel diseases* **15**,
32 1599-1604, doi:10.1002/ibd.21034 (2009).
33 86 De Cruz, P., Kamm, M. A., Prideaux, L., Allen, P. B. & Moore, G. Mucosal healing in
34 Crohn's disease: a systematic review. *Inflammatory bowel diseases* **19**, 429-444,
35 doi:10.1002/ibd.22977 (2013).
36 87 Mary, J. Y. & Modigliani, R. Development and validation of an endoscopic index of
37 the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes
38 Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut* **30**,
39 983-989 (1989).
40 88 Daperno, M. *et al.* Development and validation of a new, simplified endoscopic
41 activity score for Crohn's disease: the SES-CD. *Gastrointestinal endoscopy* **60**, 505-
42 512 (2004).
43 89 Rutgeerts, P. *et al.* Predictability of the postoperative course of Crohn's disease.
44 *Gastroenterology* **99**, 956-963 (1990).
45 90 Rutgeerts, P. *et al.* Natural history of recurrent Crohn's disease at the ileocolonic
46 anastomosis after curative surgery. *Gut* **25**, 665-672 (1984).

- 91 D'Haens, G. R. *et al.* Early lesions of recurrent Crohn's disease caused by infusion of
92 intestinal contents in excluded ileum. *Gastroenterology* **114**, 262-267 (1998).
- 93 Korelitz, B. I. & Sommers, S. C. Response to drug therapy in Crohn's disease:
94 evaluation by rectal biopsy and mucosal cell counts. *Journal of clinical
95 gastroenterology* **6**, 123-127 (1984).
- 96 Molander, P. *et al.* Achievement of deep remission during scheduled maintenance
97 therapy with TNFalpha-blocking agents in IBD. *Journal of Crohn's & colitis* **7**, 730-735,
98 doi:10.1016/j.crohns.2012.10.018 (2013).
- 99 D'Haens, G. *et al.* Endoscopic and histological healing with infliximab anti-tumor
100 necrosis factor antibodies in Crohn's disease: A European multicenter trial.
101 *Gastroenterology* **116**, 1029-1034 (1999).
- 102 Geboes, K. *et al.* Endoscopic and histologic evidence of persistent mucosal healing
103 and correlation with clinical improvement following sustained infliximab treatment
104 for Crohn's disease. *Current medical research and opinion* **21**, 1741-1754,
105 doi:10.1185/030079905x65457 (2005).
- 106 Panes, J. *et al.* Systematic review: the use of ultrasonography, computed
107 tomography and magnetic resonance imaging for the diagnosis, assessment of
108 activity and abdominal complications of Crohn's disease. *Alimentary pharmacology
109 & therapeutics* **34**, 125-145, doi:10.1111/j.1365-2036.2011.04710.x (2011).
- 110 Craig, O. *et al.* Diagnostic accuracy of computed tomography using lower doses of
111 radiation for patients with Crohn's disease. *Clinical gastroenterology and hepatology
112 : the official clinical practice journal of the American Gastroenterological Association*
113 **10**, 886-892, doi:10.1016/j.cgh.2012.03.014 (2012).
- 114 Kuehle, C. A. *et al.* Hydro-MRI of the small bowel: effect of contrast volume, timing
115 of contrast administration, and data acquisition on bowel distention. *AJR. American
116 journal of roentgenology* **187**, W375-385, doi:10.2214/ajr.05.1079 (2006).
- 117 Rimola, J. *et al.* Magnetic resonance imaging for evaluation of Crohn's disease:
118 validation of parameters of severity and quantitative index of activity. *Inflammatory
119 bowel diseases* **17**, 1759-1768, doi:10.1002/ibd.21551 (2011).
- 120 Rimola, J. *et al.* Magnetic resonance for assessment of disease activity and severity in
121 ileocolonic Crohn's disease. *Gut* **58**, 1113-1120, doi:10.1136/gut.2008.167957
122 (2009).
- 123 Ordas, I. *et al.* Accuracy of magnetic resonance enterography in assessing response
124 to therapy and mucosal healing in patients with Crohn's disease. *Gastroenterology*
125 **146**, 374-382.e371, doi:10.1053/j.gastro.2013.10.055 (2014).
- 126 Cipriano, L. E., Levesque, B. G., Zaric, G. S., Loftus, E. V., Jr. & Sandborn, W. J. Cost-
127 effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's
128 disease. *Inflammatory bowel diseases* **18**, 1240-1248, doi:10.1002/ibd.21862 (2012).
- 129 Van Assche, G. *et al.* Magnetic resonance imaging of the effects of infliximab on
130 perianal fistulizing Crohn's disease. *The American journal of gastroenterology* **98**,
131 332-339, doi:10.1111/j.1572-0241.2003.07241.x (2003).
- 132 Parks, A. G., Gordon, P. H. & Hardcastle, J. D. A classification of fistula-in-ano. *The
133 British journal of surgery* **63**, 1-12 (1976).
- 134 Martinez, M. J., Ripolles, T., Paredes, J. M., Blanc, E. & Marti-Bonmati, L. Assessment
135 of the extension and the inflammatory activity in Crohn's disease: comparison of
136 ultrasound and MRI. *Abdominal imaging* **34**, 141-148, doi:10.1007/s00261-008-
137 9365-y (2009).

- 106 Migaleddu, V. *et al.* Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. *Gastroenterology* **137**, 43-52, doi:10.1053/j.gastro.2009.03.062 (2009).
- 107 Neye, H. *et al.* Evaluation of criteria for the activity of Crohn's disease by power Doppler sonography. *Digestive diseases (Basel, Switzerland)* **22**, 67-72, doi:10.1159/000078737 (2004).
- 108 Limberg, B. [Diagnosis of chronic inflammatory bowel disease by ultrasonography]. *Zeitschrift fur Gastroenterologie* **37**, 495-508 (1999).
- 109 Paredes, J. M. *et al.* Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. *Digestive diseases and sciences* **55**, 404-410, doi:10.1007/s10620-009-0759-7 (2010).
- 110 Calabrese, E. *et al.* Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. *Journal of Crohn's & colitis* **6**, 852-860, doi:10.1016/j.crohns.2012.01.015 (2012).
- 111 Moreno, N. *et al.* Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with immunomodulators and/or anti-TNF antibodies. *Journal of Crohn's & colitis* **8**, 1079-1087, doi:10.1016/j.crohns.2014.02.008 (2014).
- 112 Zorzi, F. *et al.* A sonographic lesion index for Crohn's disease helps monitor changes in transmural bowel damage during therapy. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* **12**, 2071-2077, doi:10.1016/j.cgh.2014.04.036 (2014).
- 113 Calabrese, E. *et al.* Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* **11**, 950-955, doi:10.1016/j.cgh.2013.01.015 (2013).
- 114 Castiglione, F. *et al.* Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. *Inflammatory bowel diseases* **14**, 1240-1245, doi:10.1002/ibd.20469 (2008).
- 115 Novak, K. *et al.* Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. *Journal of Crohn's & colitis* **9**, 795-801, doi:10.1093/ecco-jcc/jjv105 (2015).
- 116 Kiss, L. S. *et al.* Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. *Alimentary pharmacology & therapeutics* **34**, 911-922, doi:10.1111/j.1365-2036.2011.04827.x (2011).
- 117 Hanauer, S. B. *et al.* Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* **130**, 323-333; quiz 591, doi:10.1053/j.gastro.2005.11.030 (2006).
- 118 Lamireau, T. *et al.* Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. *Inflammatory bowel diseases* **10**, 745-750 (2004).
- 119 Rutgeerts, P. *et al.* Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology* **117**, 761-769 (1999).
- 120 Targan, S. R. *et al.* A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *The New*

- 1 *England journal of medicine* **337**, 1029-1035, doi:10.1056/nejm199710093371502
2 (1997).
- 3 121 Reinisch, W. *et al.* Factors associated with short- and long-term outcomes of therapy
4 for Crohn's disease. *Clinical gastroenterology and hepatology : the official clinical*
5 *practice journal of the American Gastroenterological Association* **13**, 539-547.e532,
6 doi:10.1016/j.cgh.2014.09.031 (2015).
- 7 122 Sipponen, T. *et al.* Faecal calprotectin and lactoferrin are reliable surrogate markers
8 of endoscopic response during Crohn's disease treatment. *Scandinavian journal of*
9 *gastroenterology* **45**, 325-331, doi:10.3109/00365520903483650 (2010).
- 10 123 Kiss, L. S. *et al.* High-sensitivity C-reactive protein for identification of disease
11 phenotype, active disease, and clinical relapses in Crohn's disease: a marker for
12 patient classification? *Inflammatory bowel diseases* **18**, 1647-1654,
13 doi:10.1002/ibd.21933 (2012).
- 14 124 Henderson, P. *et al.* Serum C-reactive protein and CRP genotype in pediatric
15 inflammatory bowel disease: influence on phenotype, natural history, and response
16 to therapy. *Inflammatory bowel diseases* **21**, 596-605,
17 doi:10.1097/mib.0000000000000296 (2015).
- 18 125 Click, B. *et al.* Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive
19 Protein Are at Risk for Subsequent Hospitalization. *Inflammatory bowel diseases* **21**,
20 2254-2261, doi:10.1097/mib.0000000000000516 (2015).
- 21 126 Kennedy, N. A. *et al.* Thiopurine withdrawal during sustained clinical remission in
22 inflammatory bowel disease: relapse and recapture rates, with predictive factors in
23 237 patients. *Alimentary pharmacology & therapeutics* **40**, 1313-1323,
24 doi:10.1111/apt.12980 (2014).
- 25 127 Louis, E. *et al.* Maintenance of remission among patients with Crohn's disease on
26 antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology* **142**,
27 63-70 e65; quiz e31, doi:10.1053/j.gastro.2011.09.034 (2012).
- 28 128 Treton, X. *et al.* Azathioprine withdrawal in patients with Crohn's disease maintained
29 on prolonged remission: a high risk of relapse. *Clinical gastroenterology and*
30 *hepatology : the official clinical practice journal of the American Gastroenterological*
31 *Association* **7**, 80-85, doi:10.1016/j.cgh.2008.08.028 (2009).
- 32 129 Reinisch, W., Wang, Y., Oddens, B. J. & Link, R. C-reactive protein, an indicator for
33 maintained response or remission to infliximab in patients with Crohn's disease: a
34 post-hoc analysis from ACCENT I. *Alimentary pharmacology & therapeutics* **35**, 568-
35 576, doi:10.1111/j.1365-2036.2011.04987.x (2012).
- 36 130 Jones, J. *et al.* Relationships between disease activity and serum and fecal
37 biomarkers in patients with Crohn's disease. *Clinical gastroenterology and*
38 *hepatology : the official clinical practice journal of the American Gastroenterological*
39 *Association* **6**, 1218-1224, doi:10.1016/j.cgh.2008.06.010 (2008).
- 40 131 Zubin, G. & Peter, L. Predicting Endoscopic Crohn's Disease Activity Before and After
41 Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and
42 Fecal Calprotectin. *Inflammatory bowel diseases* **21**, 1386-1391,
43 doi:10.1097/mib.0000000000000388 (2015).
- 44 132 Chamouard, P., Richert, Z., Meyer, N., Rahmi, G. & Baumann, R. Diagnostic value of
45 C-reactive protein for predicting activity level of Crohn's disease. *Clinical*
46 *gastroenterology and hepatology : the official clinical practice journal of the*

- 1 *American Gastroenterological Association* **4**, 882-887, doi:10.1016/j.cgh.2006.02.003
2 (2006).
- 3 133 Karoui, S. *et al.* Correlation between levels of C-reactive protein and clinical activity
4 in Crohn's disease. *Digestive and liver disease : official journal of the Italian Society of*
5 *Gastroenterology and the Italian Association for the Study of the Liver* **39**, 1006-1010,
6 doi:10.1016/j.dld.2007.06.015 (2007).
- 7 134 Florin, T. H., Paterson, E. W., Fowler, E. V. & Radford-Smith, G. L. Clinically active
8 Crohn's disease in the presence of a low C-reactive protein. *Scandinavian journal of*
9 *gastroenterology* **41**, 306-311, doi:10.1080/00365520500217118 (2006).
- 10 135 Yang, D. H. *et al.* Usefulness of C-reactive protein as a disease activity marker in
11 Crohn's disease according to the location of disease. *Gut and liver* **9**, 80-86,
12 doi:10.5009/gnl13424 (2015).
- 13 136 Wright, E. K. *et al.* Measurement of fecal calprotectin improves monitoring and
14 detection of recurrence of Crohn's disease after surgery. *Gastroenterology* **148**, 938-
15 947 e931, doi:10.1053/j.gastro.2015.01.026 (2015).
- 16 137 Cerrillo, E. *et al.* Fecal Calprotectin in Ileal Crohn's Disease: Relationship with
17 Magnetic Resonance Enterography and a Pathology Score. *Inflammatory bowel*
18 *diseases* **21**, 1572-1579, doi:10.1097/mib.0000000000000404 (2015).
- 19 138 Schoepfer, A. M. *et al.* Fecal calprotectin more accurately reflects endoscopic activity
20 of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets,
21 hemoglobin, and blood leukocytes. *Inflammatory bowel diseases* **19**, 332-341,
22 doi:10.1097/MIB.0b013e3182810066 (2013).
- 23 139 D'Haens, G. *et al.* Fecal calprotectin is a surrogate marker for endoscopic lesions in
24 inflammatory bowel disease. *Inflammatory bowel diseases* **18**, 2218-2224,
25 doi:10.1002/ibd.22917 (2012).
- 26 140 Ferreiro-Iglesias, R. *et al.* Fecal Calprotectin as Predictor of Relapse in Patients With
27 Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. *Journal of*
28 *clinical gastroenterology*, doi:10.1097/mcg.0000000000000312 (2015).
- 29 141 Mooiweer, E. *et al.* Low fecal calprotectin predicts sustained clinical remission in
30 inflammatory bowel disease patients: a plea for deep remission. *Journal of Crohn's &*
31 *colitis* **9**, 50-55, doi:10.1093/ecco-jcc/jju003 (2015).
- 32 142 De Cruz, P. *et al.* Postoperative recurrence of Crohn's disease: impact of endoscopic
33 monitoring and treatment step-up. *Colorectal disease : the official journal of the*
34 *Association of Coloproctology of Great Britain and Ireland* **15**, 187-197,
35 doi:10.1111/j.1463-1318.2012.03168.x (2013).
- 36 143 Gecse, K. B. *et al.* Impact of disease location on fecal calprotectin levels in Crohn's
37 disease. *Scandinavian journal of gastroenterology* **50**, 841-847,
38 doi:10.3109/00365521.2015.1008035 (2015).
- 39 144 Allen, P. B. & Peyrin-Biroulet, L. Moving towards disease modification in
40 inflammatory bowel disease therapy. *Current opinion in gastroenterology* **29**, 397-
41 404, doi:10.1097/MOG.0b013e3283622914 (2013).
- 42 145 Peyrin-Biroulet, L. *et al.* Defining Disease Severity in Inflammatory Bowel Diseases:
43 Current and Future Directions. *Clinical gastroenterology and hepatology : the official*
44 *clinical practice journal of the American Gastroenterological Association*,
45 doi:10.1016/j.cgh.2015.06.001 (2015).
- 46
- 47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Author contributions:

All authors contributed equally to this article.

Competing interests:

A.J.W.has served as an advisory board member for AbbVie, Ferring, Janssen-Cilag, Hospira and Takeda. She has received honoraria for speaking from AbbVie, Ferring, Janssen-Cilag and Shire, and has received grants for support of research from AbbVie, Ferring, Janssen-Cilag and Shire.

R.V.B. has received conference attendance support from Ferring, Janssen, and Takeda, and honoraria for speaking from Abbvie, Janssen-Cilag and Shire, , and.

S.P.L.T. has received grants for research support from AbbVie, Lilly, Norman Collison Foundation, UCB and Vifor. He has received consulting and/or speaker fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cosmo, Ferring, Giuliani SpA, GlaxoSmithKline, Lilly, MSD, Neovacs, Novartis, Norman Collison Foundation, Novo Nordisk, Pfizer, Proximagen, Receptos, Shire, Sigmoid Pharma, Takeda, TopiVert, UCB, VHsquared, Vifor, and Warner Chilcott.

Review criteria

A literature search was performed to evaluate available disease activity assessment indices within each of the prescribed domains; clinical, endoscopic, histologic, and radiologic assessment, biomarkers and quality of life (See [Supplementary Information S4 \(box\) online](#)).

FURTHER INFORMATION

WWW.ICHOM.ORG

Supplementary Information

See online article: S1 (tables) | S2 (tables) | S3 (file) | S4 (box)

Figure 1 | Domains of disease activity assessment.

Domains of disease activity assessment in IBD overlap, and consist of inflammation, clinical symptoms and quality of life. Inflammation can be assessed by endoscopy, histology, imaging and/or biomarkers.

Table 1: Ulcerative colitis disease activity assessment indices in clinical practice

Domain	Index Name	Abbreviation	Range and remission threshold	Strengths	Weaknesses	Suppl. Table Number
Clinical	Simple Clinical Colitis Activity Index ¹⁰	SCCAI	0–19 Remission: ≤2	Able to be completed by patient Includes important factors such as urgency, incontinence and nocturnal bowel movements Reliable, valid, responsive and feasible	Not validated	1
	Partial Mayo Index ^{11,12}	NA	0–9 Remission: ≤1	Most widely used Discriminates remission from active disease	Not validated Relies on subjective Physician Global assessment	2
	Pediatric Ulcerative Colitis Activity Index ¹³	PUCAI	0–85 Remission: <10	Validated Reliable and responsive in adults Might permit less frequent endoscopic assessment	Has not been widely adopted in the adult population	3
	Truelove and Witts' Severity Index ¹⁴	TWC		Objective criteria for acute severe colitis. Useful for prognosis	Not validated, although widely used	4

Endoscopic	Mayo Clinic Index: endoscopic sub-score ¹¹		0–3 Remission: ≤1	Easy to use Commonly used in clinical trials and clinical practice	Overlap of the different levels results in low inter-observer agreement No validated definition of mucosal healing Subjective terms (minimal or slight friability) reduce concordance Does not consider disease extent	5
	Ulcerative Colitis Endoscopic Index of Severity ^{8,9}	UCEIS	0–8 Remission: ≤1	Validated Easy to use High inter-observer reproducibility Accounts for 88% of variation between observers Now used in clinical trials	No validated definition of mucosal healing or response Does not consider disease extent No thresholds for mild, moderate and severe disease	6
Histology	Riley Score ³⁸	NA	0–18	Widely used, simple, predictive value in outcomes in ulcerative colitis	Partially validated, includes items with poor reproducibility	7
	Geboes Score ³⁹	NA	0.0–5.4 Remission: <3.1	Widely used, predicts value in outcomes in ulcerative colitis	Partially validated, includes items with poor reproducibility	8
	Nancy Histological Index ⁶	NA	0–4 Remission: 0	Validated, responsive, good intra- and inter-observer agreement Reliable, simple, and easy to use	Lacks data on predictive value on outcomes in ulcerative colitis	9
	Robarts histopathological index ³⁴	RHI	0–12 Remission: ≤6	Validated and responsive (compared with endoscopic and QOL indices)	Lack data on predictive value on outcomes in ulcerative colitis	10
Radiology	Magnetic resonance colonography simplified index ⁴⁷	MRC-S	0–4 Remission: 0	Simple and correlates well with endoscopic disease activity	Not validated Cost and availability of MRI and requirement for bowel preparation	11
	Segmental magnetic resonance score ⁴⁸	MR-score-S	0–6 Remission: 0	Good reproducibility and inter-observer agreement, correlates well with endoscopic features No need for bowel preparation	Not validated. Cost and availability of MRI	12
	Bowel Ultrasound Severity Score ⁴⁹	NA	0–3 Remission: 0	High concordance between US score and endoscopic disease activity	Not validated. Dependent on expert and experienced	13

				Bowel US score predictive of outcomes in ulcerative colitis	sonographer	
Biomarkers	C-reactive protein	CRP	0 to >200mg/l (1904nmol/l) Remission: ≤3 to <19 mg/l	Predictive of outcomes in acute severe colitis (Oxford criteria*) Widely available	Less useful in mild disease Poor correlation with endoscopic disease activity	14
	Faecal calprotectin	FC	0 to >1000µg/g Remission: <50 to <250 µg/g	Useful for monitoring disease activity in ulcerative colitis (using ΔFC)	Wide range of cut-off values for determining active vs inactive disease Lacks sensitivity and specificity for endoscopy disease activity	NA
Quality of Life	IBD-Control	IBD-Control	Maximum of 16 for IBD-Control-8 (16 = best quality of life)	Easy to use. No licensing fee. Captures disease control from patient's perspective.	Calculating total score requires the answers to be translated.	15
	Short Inflammatory Bowel Disease Questionnaire ⁷⁶	SIBDQ	10–70	Easy to use Results correlate to the longer 32-item IBDQ Widely accepted Validated Reproducible and responsive	Licensing fee required for use	16
	Crohn's Ulcerative Colitis Questionnaire ⁷⁷	CUCQ-8	0–8	Easy to use Results correlate with longer 32-item questionnaire Validated No licensing fee	Calculating total score requires each question to be translated into a subscore out of 1.	17

1 For a full list of identified indices, please see Supplementary information S1 (table 1).

2 *Oxford criteria defined as more than eight stools per day or 3–8 stools per day and
3 plasma CRP concentration >45 mg/l. FC, faecal calprotectin; NA, not applicable;
4 QOL, quality of life; US, ultrasonography.

5

6 **Table 2: Crohn's disease activity assessment indices in clinical practice**

7

Domain	Index Name	Abbreviation	Range (remission threshold)	Strengths	Weaknesses	Suppl. Table Number
Clinical	Crohn's Disease Activity Index ⁸⁰	CDAI	0–600 Remission: <150	Widely used.	Complex calculation involving a 7-day diary High variability Low contribution to total score for perianal disease	18
	Harvey-Bradshaw Index ⁸²	HBI	0–50 Remission: ≤4	Simpler, less cumbersome Does not require a 7-day diary Correlates well with CDAI	Low contribution to total score for perianal disease	19

	Perianal Crohn's Disease Activity Index ⁸⁴	PDAI	0–19	Easy to use	Does not allow documentation of fistula severity	20
Endoscopic	Crohn's Disease Endoscopic Index of Severity ⁸⁷	CDEIS	0–44 Remission: <3	Current gold-standard Reproducible and validated Extensively used in clinical trials	Complex Cumbersome to use in clinical practice Needs experience and training No validated definition of mucosal healing No correlation with CDAI	21
	Simple Endoscopic Score for Crohn's disease ⁸⁸	SES-CD	0–56	Simplified version of the CDEIS. Validated Performance correlates well with CDEIS	Only slightly less complex than CDEIS Validated against CDEIS in only one study No validated definition of mucosal healing No correlation with CDAI Less frequently used in clinical trials	22
	Rutgeerts' Post-operative Endoscopic Index ^{89,90}	NA	i0 to i4 Remission: <i2	Standard for evaluating post-operative recurrence Strong prognostic relevance Widely used in clinical practice and trials	Discriminative ability unclear, especially of the i2 domain Only for use after ileocolic resection	23
Histology	Colonic and Ileal Global Histologic Disease Activity Score ^{91,95}	CGHAS IGHAS	0–16	Takes into account patchy disease activity	Not validated. No data on reproducibility. Inherent issues with histological scoring in Crohn's disease	24
Radiology	Magnetic Resonance Index of Activity ⁹⁹⁻¹⁰¹	MaRIA	Segmental mucosal healing <7 Segmental ulcer healing <11	Validated. Good intra-observer and inter-observer concordance, correlates well with endoscopy Responsive index	Might be best used in clinical trials rather than clinical practice	25
	Van Assche MRI-Based Score for Severity of Perianal Crohn's Disease ¹⁰³	NA	0–24	Validated Good inter-observer concordance	Utility in clinical practice might be limited due to complexity	26
	Limberg scoring system for bowel ultrasonography ¹⁰⁸	Limberg Score	0–4	Widely used	Not validated	27

Biomarkers	C-reactive protein	CRP	0 to >200mg/l Remission: ≤5 to <8 mg/l	Useful for monitoring disease activity in Crohn's disease Predictive of relapse whilst on therapy and following withdrawal	Modest correlation with endoscopic disease activity (especially ileal disease)	NA
	Faecal calprotectin	FC	0 to >1000µg/g Remission: <50 to <250 µg/g	Useful for monitoring disease activity in Crohn's disease (using ΔFC)	Wide range of cut-off values for determining active vs inactive disease. Lacks sensitivity and specificity for endoscopy disease activity	NA
Quality of Life	IBD-Control (IBD-Control-8 also used)	IBD-Control IBD-Control-8	Maximum score of [Au:Can you provide the maximum score?] for full score Maximum of 16 for IBD-Control-8 (16 = best quality of life)	Easy to use. No licensing fee. Captures disease control from patient's perspective.	Calculating total score requires the answers to be translated.	15
	Short Inflammatory Bowel Disease Questionnaire ⁷⁶	SIBDQ	10–70 (10 = best QOL)	Easy to calculate total score. Results correlate to the longer 32-item IBDQ Widely accepted Validated Reproducible and responsive	Licensing fee required for use	16
	Crohn's Ulcerative Colitis Questionnaire-8 ⁷⁷	CUCQ-8	0–8 (0 = best QOL)	Easy to use Results correlate with longer 32-item questionnaire Validated No licensing fee	Calculating total score requires each question to be translated into a subscore out of 1.	17

1

2 For a full list of identified indices, please see Supplementary information S1 (table 2). FC,

3 faecal calprotectin; NA, not applicable; QOL, quality of life.

4

5

6

7

8

Online only info

Author biographies:

Simon Travis is the Professor of Clinical Gastroenterology at the University of Oxford, UK, and a former President of the European Crohn's and Colitis Organisation (2012–2014). He is a Fellow of Linacre College and Consultant Gastroenterologist at Oxford University Hospitals NHS Trust, with research interests in predictive factors, clinical trial outcomes, novel therapy, endoscopic assessment and patient-reported outcomes for inflammatory bowel disease.

Robert Bryant is a Consultant Gastroenterologist at the Royal Adelaide Hospital, Australia, and a PhD candidate at the University of Adelaide. He undertook a Clinical Fellowship in Inflammatory Bowel Diseases within the Oxford University Hospitals NHS Trust (2013–2014) and thereafter a Master of Science by Research at the University of Oxford (2014–2015). He is actively involved in research involving diet, body composition, disease activity assessment, optimizing outcomes, and predictive factors in inflammatory bowel disease.

Alissa Walsh is a Consultant Gastroenterologist at St Vincent's Hospital Sydney, Australia, currently undertaking a DPhil at the University of Oxford, UK. After completing her formal gastroenterology training in Australia, she undertook a Clinical Fellowship in Inflammatory Bowel Diseases within the Oxford University Hospitals NHS Trust (2007–2008) and thereafter a National Health Medical Research Council fellowship in Australia (2009–2011). She is actively involved in research involving inflammatory bowel disease activity indices, prevention of opportunistic infections in immunocompromised patients and the role of faecal transplantation in ulcerative colitis. Dr Walsh is a founder and director of Crohn's Colitis Cure and an active member of the Australia New Zealand IBD Consortium.

ToC blurb

Objective assessment of disease activity in IBD is crucial for successfully guiding therapy. Here, the authors comprehensively evaluate disease activity indices for their use in clinical practice and clinical trials, as well as assessing relevant biomarkers and measures of quality of life.

Subject terms

[Health sciences / Gastroenterology / Gastrointestinal diseases / Inflammatory bowel disease](#)
[URI /692/4020/1503/257]

[Health sciences / Signs and symptoms / Digestive signs and symptoms](#)
[URI /692/1807/1808]

[Health sciences / Health care / Quality of life](#)
[URI /692/700/784]

[Health sciences / Health care / Medical imaging](#)
[URI /692/700/1421]